Search clinical trials for: MDX-010

Total 5723 results

Bristol-Myers Squibb

Withdrawn

MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma

Lymphoma, Large-Cell

United States, France
Bristol-Myers Squibb

Completed

Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer

Prostate Cancer

United States
National Cancer Institute (NCI)

Withdrawn

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative... and other conditions
Emory University
Bristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of... and other collaborators

Active, not recruiting

VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma

Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma

Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Kidney Medullary Carcinoma | Loss of INI 1 Protein Expression

United States
Bristol-Myers Squibb

Completed

Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer

Neoplasm Metastasis | Prostate Cancer

United States
Azura Ophthalmics
Syneos Health; Cliantha Research

Completed

A Multicenter Study Evaluating AZR-MD-001 in Patients With Meibomian Gland Dysfunction and Evaporative Dry Eye Disease (DED)

Dry Eye | Meibomian Gland Dysfunction

Canada, Australia, New Zealand
Center Trials & Treatment
BioGene Pharmaceutical Inc.

No longer available

An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas

Glioblastoma | Glioma of Brain

Bosnia and Herzegovina, Albania, Bulgaria, Croatia, Romania, Russian Federation, Serbia, Switzerland
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Allogeneic Hematopoietic Stem Cell Transplantation Recipient

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer

Hepatocellular Carcinoma | Resectable Hepatocellular Carcinoma

United States
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

United States, Germany, Spain, United Kingdom, Italy, Canada, Denmark, Finland
Bristol-Myers Squibb

Completed

Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

Malignant Melanoma

United States
Celero Systems, Inc.

Recruiting

Tolerability of a Modified Health-Dx

Healthy Volunteers

United States
Azura Ophthalmics
ORA, Inc.

Not yet recruiting

A Phase 3 Study to Evaluate AZR-MD-001 in Patients With Abnormal Meibomian Gland Function and Dry Eye Disease (DED)

Dry Eye Disease

United States
Bristol-Myers Squibb

Completed

Study of MDX-010 in Stage IV Breast Cancer

Adenocarcinoma | Breast Cancer

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Bristol-Myers Squibb

Completed

Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma

Recurrent Melanoma | Stage IV Melanoma | Tumors Metastatic to Brain

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Completed

Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7 (STARVE-PC)

Prostate Cancer | Recurrent Prostate Carcinoma | Stage IV Prostate Adenocarcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

Metastatic Uveal Melanoma | Stage IV Uveal Melanoma AJCC v7

United States
Jonsson Comprehensive Cancer Center
Bristol-Myers Squibb

Completed

Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery

Gastrointestinal Stromal Tumor

United States
Northwestern University
Bristol-Myers Squibb; National Cancer Institute (NCI)

Terminated

Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer

Stage IV Breast Cancer | HER2/Neu Negative | Recurrent Inflammatory Breast Carcinoma | Stage IV Inflammatory Breast Carcinoma

United States
Emory University
Vaccinex Inc.

Recruiting

VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck

United States
Northwestern University
Bristol-Myers Squibb; National Cancer Institute (NCI)

Active, not recruiting

Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer

Major Salivary Gland Carcinoma | Recurrent Salivary Gland Carcinoma | Stage IVA Major Salivary Gland Carcinoma | Stage IVB Major Salivary Gland Carcinoma | Stage IVC Major Salivary Gland Carcinoma | Minor Salivary Gland Carcinoma | Stage IV Major Salivary Gland Carcinoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma

Pleural Biphasic Mesothelioma | Pleural Sarcomatoid Mesothelioma

United States
Azura Ophthalmics
Avania

Completed

Evaluation of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD)

Meibomian Gland Dysfunction

Australia, New Zealand
Bristol-Myers Squibb
Medarex

Completed

A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus (HIV)

Human Immunodeficiency Virus (HIV)

United States
Bristol-Myers Squibb

Active, not recruiting

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

Unresectable or Metastatic Melanoma

United States, France, Poland, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, Germany, Ireland, Israel, Italy, Netherlands, New Zealand, Norway, Spain, Sweden, Switzerland, United Kingdom, Russian Federation
Azura Ophthalmics
The University of New South Wales

Completed

An Evaluation of AZR-MD-001 as Treatment for Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD)

Meibomian Gland Dysfunction (MGD) | Contact Lens Discomfort (CLD)

Australia
Boston Children's Hospital
United States Department of Defense; National Football League

Completed

LED Therapy for the Treatment of Concussive Brain Injury

Brain Concussion

United States
Bristol-Myers Squibb

Completed

Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma

Melanoma

United States
University Hospital Southampton NHS Foundation...
Bristol-Myers Squibb; Cancer Research UK; Institute of Cancer Research, United...

Completed

The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer (ICE)

Extensive Stage Small Cell Lung Cancer

United Kingdom
National Cancer Institute (NCI)

Completed

Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome

United States
Celldex Therapeutics

Terminated

A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma

Kidney Neoplasms | Metastatic Renal Cell Carcinoma | Ovarian Clear Cell Carcinoma | Papillary Renal Cell Carcinoma | Renal Cell Carcinoma (RCC) | Clear-cell Renal Cell Carcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer

Metastatic Colorectal Adenocarcinoma | Advanced Colon Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer... and other conditions

United States
OncoImmune, Inc.
National Cancer Institute (NCI); Huntsman Cancer Institute

Withdrawn

CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI) (CINDI)

Metastatic Melanoma

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Recruiting

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditions

United States
Prolacta Bioscience

Recruiting

Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell Transplantation

Hematologic Malignancy

United States
Pendulum Therapeutics

Completed

Placebo-Controlled Clinical Nutrition Study of the Safety and Metabolic Effects of Two Medical Foods in Type 2 Diabetes

Type 2 Diabetes Mellitus

United States
Diwakar Davar

Completed

Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma

Melanoma

United States
Providence Health & Services
Bristol-Myers Squibb

Active, not recruiting

Ipilimumab for Head and Neck Cancer Patients

Squamous Cell Carcinoma of the Head and Neck

United States
Diwakar Davar
Bristol-Myers Squibb

Completed

Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma

Melanoma

United States
Bristol-Myers Squibb

Withdrawn

Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia

Leukemia, Myeloid, Chronic

United States
Alzeca Biosciences, Inc.
pharmtrace klinische Entwicklung GmbH

Recruiting

Proof-of-concept Study of New Imaging Diagnostic in Patients With Suspected Alzheimer's Disease

Alzheimer Disease

Germany
National Cancer Institute (NCI)

Completed

Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant

Recurrent Hodgkin Lymphoma | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Recurrent Non-Hodgkin Lymphoma | Recurrent Acute Lymphoblastic Leukemia | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Plasma Cell Myeloma | Myeloproliferative Neoplasm | Recurrent... and other conditions

United States
NewLink Genetics Corporation

Terminated

Immunotherapy Study for Patients With Stage IV Melanoma

Metastatic Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Completed

Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer

Cervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IVA Cervical Cancer AJCC v6 and v7 | Recurrent Cervical Carcinoma | Human Papillomavirus Infection | Stage IVB Cervical Cancer AJCC v6 and v7

United States, Canada
Robert Lowsky
National Cancer Institute (NCI)

Completed

A Phase I/II Study of Intratumoral Injection of SD-101

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma | Recurrent Small Lymphocytic...

United States
Bristol-Myers Squibb

Completed

Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection

Urothelial Carcinoma

United States
Bristol-Myers Squibb

Completed

Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)

Unresectable Stage III or IV Malignant Melanoma

United States, Peru, Norway, Italy, Sweden, Denmark, Israel
Bristol-Myers Squibb

Completed

A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies

Melanoma

South Africa, United States, Spain, France, Italy, Belgium, Austria, Israel, Germany, Norway, Canada, Brazil, Poland, Denmark, Czech Republic, Russian Federation, Ukraine, Argentina

Search clinical trials for: MDX-010

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations